Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma

BACKGROUND: PD-1-based immune checkpoint blockade (ICB) is a highly effective therapy in metastatic melanoma. However, 40-60% of patients are primarily resistant, with valid predictive biomarkers currently missing. This study investigated the digitally quantified tumor PD-L1 expression for ICB thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Placke, Jan-Malte, Soun, Camille, Bottek, Jenny, Herbst, Rudolf, Terheyden, Patrick, Utikal, Jochen, Pföhler, Claudia, Ulrich, Jens, Kreuter, Alexander, Pfeiffer, Christiane, Mohr, Peter, Gutzmer, Ralf, Meier, Friedegund, Dippel, Edgar, Weichenthal, Michael, Zimmer, Lisa, Livingstone, Elisabeth, Becker, Jürgen C., Lodde, Georg, Sucker, Antje, Griewank, Klaus, Horn, Susanne, Hadaschik, Eva, Roesch, Alexander, Schadendorf, Dirk, Engel, Daniel Robert, Ugurel, Selma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491983/
https://www.ncbi.nlm.nih.gov/pubmed/34621681
http://dx.doi.org/10.3389/fonc.2021.741993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491983/
https://www.ncbi.nlm.nih.gov/pubmed/34621681
http://dx.doi.org/10.3389/fonc.2021.741993

Ejemplares similares